Hidradenitis suppurativa

Dermatologic Clinics

Volumn 28, Issue 4, 2010, Pages 779-793

  Danby, F William ^a,b   Margesson, Lynette J ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Danby and Margesson   (United States)

Author keywords

Acne inversus; Diet; Follicular hyperkeratosis; Hidradenitis suppurativa; Treatment

Indexed keywords

ADALIMUMAB; ANDROGEN; ANTIANDROGEN; ANTIBIOTIC AGENT; BOTULINUM TOXIN; CLINDAMYCIN; CYCLOSPORIN; CYPROTERONE ACETATE; DAPSONE; DIANE; DUTASTERIDE; ETANERCEPT; ETHINYLESTRADIOL PLUS NORGESTREL; FINASTERIDE; GLUCONATE ZINC; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; MINOCYCLINE; NICOTINE; PLACEBO; RAPAMYCIN; RETINOID; RIFAMPICIN; SPIRONOLACTONE; STEROID; TETRACYCLINE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ACNE; ADL DISABILITY; ANEMIA; ANUS FISTULA; ARTHROPATHY; CHROMOSOME 1P; CLINICAL FEATURE; CLINICAL TRIAL; COPPER METABOLISM; DAIRY PRODUCT; DELAYED DIAGNOSIS; DIAGNOSTIC ERROR; DIARRHEA; DIET RESTRICTION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILY HISTORY; GASTROINTESTINAL SYMPTOM; GLYCEMIC LOAD; HEARING IMPAIRMENT; HORMONAL REGULATION; HORMONE SENSITIVITY; HUMAN; ICHTHYOSIS; INFECTION; INNATE IMMUNITY; KERATITIS; LOW DRUG DOSE; LUPUS LIKE SYNDROME; MENSTRUAL IRREGULARITY; NEUROPATHY; ONSET AGE; PATHOGENESIS; PHOTODYNAMIC THERAPY; PREVALENCE; PRIORITY JOURNAL; PUSTULE; QUALITY OF LIFE; REVIEW; SCAR FORMATION; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ABSCESS; SKIN DEFECT; SKIN PAIN; SMOKING HABIT; SOCIAL ISOLATION; SQUAMOUS CELL CARCINOMA; SUPPURATIVE HIDRADENITIS; SWELLING; TERATOGENICITY; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; WORK DISABILITY; WOUND DRAINAGE;

ANDROGEN ANTAGONISTS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; DIET THERAPY; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREVALENCE; QUALITY OF LIFE; RETINOIDS; SURGICAL PROCEDURES, OPERATIVE; THERAPIES, INVESTIGATIONAL;

EID: 77957112371     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.07.003     Document Type: Review

References (98)

1. Verneuil A. Etudes sur les tumeurs de la peau; de quelques maladies des grandes sudoripares. Archives Generales de Medicine 1854, 4:447-468.
2. Yu C.C., Cook M.G. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990, 122(6):763-769.
3. Sellheyer K., Krahl D. " Hidradenitis suppurativa" is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol 2005, 44(7):535-540.
4. Jansen T., Plewig G. What's new in acne inversa (alias hidradenitis suppurativa)?. J Eur Acad Dermatol Venereol 2000, 14(5):342-343.
5. Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009, 23(9):985-998.
6. Diagnostic Criteria. In: Second International HS Research Symposium 2009.
7. von der Werth J.M., Williams H.C. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000, 14(5):389-392.
8. Alikhan A., Lynch P.J., Eisen D.B. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009, 60(4):539-561.
9. Naldi L. Epidemiology. Hidradenitis suppurativa 2006, 58-64. Springer, Berlin. G. Jemec, J. Revuz, J. Leyden (Eds.).
10. Jemec G.B. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol 1988, 119(3):345-350.
11. Jemec G.B., Heidenheim M., Nielsen N.H. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996, 35(2 Pt 1):191-194.
12. Parks R.W., Parks T.G. Pathogenesis, clinical features and management of hidradenitis suppurativa. Ann R Coll Surg Engl 1997, 79(2):83-89.
13. Jemec G.B., Heidenheim M., Nielsen N.H. Hidradenitis suppurativa-characteristics and consequences. Clin Exp Dermatol 1996, 21(6):419-423.
14. Weber-LaShore A., Huppert J. Hidradenitis suppurativa in a pre-pubertal female. J Pediatr Adolesc Gynecol 2009, 22(2):e53.
15. Mengesha Y.M., Holcombe T.C., Hansen R.C. Prepubertal hidradenitis suppurativa: two case reports and review of the literature. Pediatr Dermatol 1999, 16(4):292-296.
16. Canoui-Poitrine F., Revuz J.E., Wolkenstein P., et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009, 61(1):51-57.
17. Gao M., Wang P.G., Cui Y., et al. Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p21.1-1q25.3. J Invest Dermatol 2006, 126(6):1302-1306.
18. Slade D.E., Powell B.W., Mortimer P.S. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 2003, 56(5):451-461.
19. Barth J.H., Layton A.M., Cunliffe W.J. Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. Br J Dermatol 1996, 134(6):1057-1059.
20. Kraft J.N., Searles G.E. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg 2007, 11(4):125-131.
21. Searles GE. Daily oral finasteride 5mg for hidradenitis suppurativa. Annual Meeting, Canadian Dermatology Association. Vancouver, BC (Canada), July 1-5, 2009.
22. Mortimer P.S., Dawber R.P., Gales M.A., et al. Mediation of hidradenitis suppurativa by androgens. Br Med J (Clin Res Ed) 1986, 292(6515):245-248.
23. Gupta A.K., Knowles S.R., Gupta M.A., et al. Lithium therapy associated with hidradenitis suppurativa: case report and a review of the dermatologic side effects of lithium. J Am Acad Dermatol 1995, 32(2 Pt 2):382-386.
24. Mahe E., Morelon E., Lechaton S., et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005, 79(4):476-482.
25. Revuz J. HS patients' frequently asked questions. Hidradenitis suppurativa 2006, 191. Springer, Berlin. G. Jemec, J. Revuz, J. Leyden (Eds.).
26. Hana A., Booken D., Henrich C., et al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci 2007, 80(24-25):2214-2220.
27. Konig A., Lehmann C., Rompel R., et al. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999, 198(3):261-264.
28. Kurzen H., Kurokawa I., Jemec G.B., et al. What causes hidradenitis suppurativa?. Exp Dermatol 2008, 17(5):455-456.
29. Schauber J., Gallo R.L. Expanding the roles of antimicrobial peptides in skin: alarming and arming keratinocytes. J Invest Dermatol 2007, 127(3):510-512.
30. Gniadecki R., Jemec G.B.E. Lipid raft-enriched stem cell-like keratinocytes in the epidermis, hair follicles and sinus tracts in hidradenitis suppurativa. Exp Dermatol 2004, 13:361-363. [electronic citation].
31. Williams S.T., Busby R.C., DeMuth R.J., et al. Perineal hidradenitis suppurativa: presentation of two unusual complications and a review. Ann Plast Surg 1991, 26(5):456-462.
32. Hurley H.E. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. Dermatologic surgery 1989, 729-739. Marcel Dekker, New York. R.K. Roenigk, R.H. Roenigk (Eds.).
33. Sartorius K., Emtestam L., Jemec G.B., et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009, 161(4):831-839.
34. Ramasastry S.S., Conklin W.T., Granick M.S., et al. Surgical management of massive perianal hidradenitis suppurativa. Ann Plast Surg 1985, 15(3):218-223.
35. von der Werth J.M., Jemec G.B. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001, 144(4):809-813.
36. Wolkenstein P., Loundou A., Barrau K., et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007, 56(4):621-623.
37. Wolkenstein P. Quality of life in hidradenitis suppurativa. Hidradenitis suppurativa 2006, 116-119. Springer, Berlin. G. Jemec, J. Revuz, J. Leyden (Eds.).
38. Anderson B.B., Cadogan C.A., Gangadharam D. Hidradenitis suppurativa of the perineum, scrotum, and gluteal area: presentation, complications, and treatment. J Natl Med Assoc 1982, 74(10):999-1003.
39. Anderson D.K., Perry A.W. Axillary hidradenitis. Arch Surg 1975, 110(1):69-72.
40. Scheinfeld N.S. A case of dissecting cellulitis and a review of the literature. Dermatol Online J 2003, 9(1):8.
41. Chicarilli Z.N. Follicular occlusion triad: hidradenitis suppurativa, acne conglobata, and dissecting cellulitis of the scalp. Ann Plast Surg 1987, 18(3):230-237.
42. Rosner I.A., Richter D.E., Huettner T.L., et al. Spondyloarthropathy associated with hidradenitis suppurative and acne conglobata. Ann Intern Med 1982, 97(4):520-525.
43. Bhalla R., Sequeira W. Arthritis associated with hidradenitis suppurativa. Ann Rheum Dis 1994, 53(1):64-66.
44. Libow L.F., Friar D.A. Arthropathy associated with cystic acne, hidradenitis suppurativa, and perifolliculitis capitis abscedens et suffodiens: treatment with isotretinoin. Cutis 1999, 64(2):87-90.
45. Thein M., Hogarth M.B., Acland K. Seronegative arthritis associated with the follicular occlusion triad. Clin Exp Dermatol 2004, 29(5):550-552.
46. Kahn M.F., Bouvier M., Palazzo E., et al. Sternoclavicular pustulotic osteitis (SAPHO). 20-year interval between skin and bone lesions. J Rheumatol 1991, 18(7):1104-1108.
47. Kahn M.F., Chamot A.M. SAPHO syndrome. Rheum Dis Clin North Am 1992, 18(1):225-246.
48. Church J.M., Fazio V.W., Lavery I.C., et al. The differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn's disease. Int J Colorectal Dis 1993, 8(3):117-119.
49. Cario E., Podolsky D.K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000, 68(12):7010-7017.
50. Misery I., Faure M., Claidy A. Pityriasis rubra pilaris and human immunodeficiency virus infection-type 6 pityriasis rubra pilaris?. Br J Dermatol 1996, 135(6):1008-1009.
51. Gonzalez-Lopez A., Velasco E., Pozo T., et al. HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy. Br J Dermatol 1999, 140(5):931-934.
52. Ah-Weng A., Langtry J.A., Velangi S., et al. Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol 2005, 30(6):669-671.
53. Maintz L., Betz R.C., Allam J.P., et al. Keratitis-ichthyosis-deafness syndrome in association with follicular occlusion triad. Eur J Dermatol 2005, 15(5):347-352.
54. Endo Y., Tamura A., Ishikawa O., et al. Perianal hidradenitis suppurativa: early surgical treatment gives good results in chronic or recurrent cases. Br J Dermatol 1998, 139(5):906-910.
55. Russ E., Castillo M. Lumbosacral epidural abscess due to hidradenitis suppurativa. AJR Am J Roentgenol 2002, 178(3):770-771.
56. Maalouf E., Faye O., Poli F., et al. Ann Dermatol Venereol 2006, 133(5 Pt 1):473-474. [in French].
57. Maclean G.M., Coleman D.J. Three fatal cases of squamous cell carcinoma arising in chronic perineal hidradenitis suppurativa. Ann R Coll Surg Engl 2007, 89(7):709-712.
58. Lapins J., Ye W., Nyren O., et al. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol 2001, 137(6):730-734.
59. Wiseman M.C. Hidradenitis suppurativa: a review. Dermatol Ther 2004, 17(1):50-54.
60. Rhode J.M., Burke W.M., Cederna P.S., et al. Outcomes of surgical management of stage III vulvar hidradenitis suppurativa. J Reprod Med 2008, 53(6):420-428.
61. Barron J. The surgical treatment of perianal hidradenitis suppurativa. Dis Colon Rectum 1970, 13(6):441-443.
62. Madan V., Hindle E., Hussain W., et al. Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser. Br J Dermatol 2008, 159(6):1309-1314.
63. Danby F.W. Surgical unroofing for hidradenitis suppurativa, why and how?. J Am Acad Dermatol 2010, 63:481.e1-481.e3.
64. Boer J., van Gemert M.J. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999, 40(1):73-76.
65. Lee R.A., Yoon A., Kist J. Hidradenitis suppurativa: an update. Adv Dermatol 2007, 23289-23306.
66. Brown T.J., Rosen T., Orengo I.F. Hidradenitis suppurativa. South Med J 1998, 91(12):1107-1114.
67. Harrison B.J., Mudge M., Hughes L.E. Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J (Clin Res Ed) 1987, 294(6570):487-489.
68. Clemmensen O.J. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983, 22(5):325-328.
69. Jemec G.B., Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998, 39(6):971-974.
70. Mendonca C.O., Griffiths C.E. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 2006, 154(5):977-978.
71. Kaur M.R., Lewis H.M. Hidradenitis suppurativa treated with dapsone: A case series of five patients. J Dermatolog Treat 2006, 17(4):211-213.
72. Mortimer P.S., Dawber R.P., Gales M.A., et al. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol 1986, 115(3):263-268.
73. Sawers R.S., Randall V.A., Ebling F.J. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol 1986, 115(3):269-274.
74. Stewart E.G., Margesson L.J., Danby F.W. Treatment of hidradenitis suppurativa 2009, UpToDate Online, Boston, 17.3. 11-22-2009. R.S. Berman, R.P. Dellavalle (Eds.).
75. Kurokawa I., Danby F.W., Ju Q., et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009, 18(10):821-832.
76. Golay A. Metformin and body weight. Int J Obes (Lond) 2008, 32(1):61-72.
77. Giamarellos-Bourboulis E.J., Antonopoulou A., Petropoulou C., et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 2007, 156(1):51-56.
78. Auerbach R. Treatment of hidradenitis suppurativa. JAMA 1973, 223(5):556-557.
79. Kipping H.F. How I treat hidradenitis suppurativa. Postgrad Med 1970, 48(3):291-292.
80. Camisa C., Sexton C., Friedman C. Treatment of hidradenitis suppurativa with combination hypothalamic-pituitary-ovarian and adrenal suppression. A case report. J Reprod Med 1989, 34(8):543-546.
81. Gupta A.K., Ellis C.N., Nickoloff B.J., et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990, 126(3):339-350.
82. Buckley D.A., Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med 1995, 88(5):289P-290P.
83. Rose R.F., Goodfield M.J., Clark S.M. Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin. Clin Exp Dermatol 2006, 31(1):154-155.
84. Jemec G.B. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol 2002, 27(6):528-529.
85. Martinez F., Nos P., Benlloch S., et al. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001, 7(4):323-326.
86. Grant A, Gonzalez F, Kerdel FA. Long-term efficacy and safety results (52 weeks of a double blind, placebo controlled, cross over trial of infliximab for patients with moderate to severe HS. In: Second International HS Research Symposium. San Francisco (CA), March 5, 2009.
87. Thielen A.M., Barde C., Saurat J.H. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol 2006, 155(5):1105-1107.
88. Fardet L., Dupuy A., Kerob D., et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007, 56(4):624-628.
89. Lee R.A., Dommasch E., Treat J., et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009, 60(4):565-573.
90. Blanco R., Martinez-Taboada V.M., Villa I., et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol 2009, 145(5):580-584.
91. Alexis A.F., Strober B.E. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg 2005, 9(6):296-302.
92. Brunasso A.M., Delfino C., Massone C. Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative?. Br J Dermatol 2008, 159(3):761-763.
93. Dreno B., Moyse D., Alirezai M., et al. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology 2001, 203(2):135-140.
94. Brocard A., Knol A.C., Khammari A., et al. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology 2007, 214(4):325-327.
95. Gold M., Bridges T.M., Bradshaw V.L., et al. ALA-PDT and blue light therapy for hidradenitis suppurativa. J Drugs Dermatol 2004, 3(Suppl 1):S32-S35.
96. Strauss R.M., Pollock B., Stables G.I., et al. Photodynamic therapy using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa. Br J Dermatol 2005, 152(4):803-804.
97. O'Reilly D.J., Pleat J.M., Richards A.M. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg 2005, 116(5):1575-1576.
98. Schenck S.G. Hidradenitis suppurativa axillaris; an analysis of 54 cases treated with roentgen rays. Radiology 1950, 54(1):74-77. [illust].